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Objective: Some forms of ovarian neoplasms may be preventable through the removal of 
precursor lesions.  We assessed risk associated with a prior diagnosis of, and ovarian surgery 
following, ovarian cysts and endometriosis, with a focus on characterizing risk among tumor 
subgroups. 
Methods:  Information was collected during in-person interviews with 812 women with ovarian 
cancer diagnosed in western Washington State from 2002-2005 and 1,313 population-based 
controls.  Logistic regression was used to calculate odds ratios (ORs) and 95% confidence 
intervals (CIs).  
Results:  The risk of a borderline mucinous ovarian tumor associated with a history of an ovarian 
cyst was increased (OR=1.7, 95% CI 1.0-2.8) but did not vary notably according to receipt of 
subsequent ovarian surgery.  While risk of invasive epithelial ovarian cancer was slightly 
increased among women with a cyst who had no subsequent ovarian surgery, it was reduced 
when a cyst diagnosis was followed by surgery (OR= 0.6, 95% CI 0.4-0.9).  This reduction in 
risk was most evident for serous invasive tumors.  Women with a history of endometriosis had a 
three-fold increased risk of endometrioid and clear cell invasive tumors, with a lesser risk 
increase among women who underwent subsequent ovarian surgery.   
Conclusions:  Our results suggest differences in the relation of ovarian cysts and endometriosis 
with risk of specific subtypes of ovarian cancer, as well as the possibility that ovarian surgery in 
women with these conditions may lower the risk of invasive disease.  
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Introduction 
The genesis of epithelial ovarian cancer is poorly understood, and may vary by tumor subtype.  
Among mucinous tumors, patterns of risk factors and somatic genetic alterations across benign, 
borderline and invasive subtypes are generally consistent with an adenoma-to-carcinoma 
developmental sequence, and it has therefore been hypothesized that mucinous tumors may be 
particularly amenable to risk reduction through the removal of benign precursors [1].  Some 
evidence suggests that borderline, and possibly low-grade invasive, serous tumors may similarly 
progress from their benign counterparts [2, 3]; thus, such a mechanism for risk reduction may 
extend to these tumors.  Endometrioid and clear cell ovarian tumors, which are predominantly 
invasive, may arise from foci of endometriosis [3, 4], and so may also be amenable to reducing 
risk through the removal of ovarian endometrioma.  
 
The most common ovarian cancer subtype, high-grade invasive serous disease, has long been 
posited to arise from the ovarian surface epithelium (possibly preferentially from epithelial cells 
within inclusion cysts) in the absence of a morphologically identifiable precursor [2, 5]. 
Recently, the fimbrial end of the fallopian tube has been proposed as an alternative site of origin 
for these tumors [6, 7], and some evidence of molecular precursors located in ovarian or fimbrial 
mucosal epithelium has emerged [8, 9].  Owing to their relatively undifferentiated histologic 
appearance, a substantial proportion of invasive tumors are not readily classified into any of the 
preceding histologic categories but are commonly believed to share a pathogenetic pathway with 
invasive serous tumors [5, 10, 11].   
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If some types of ovarian cancers are more likely than others to arise from benign precursors, then 
the influence of surgical removal of ovarian tissue on risk may vary by tumor subtype.  In a 
population-based case-control study of epithelial ovarian cancer conducted in Washington State, 
we assessed the risk of ovarian cancer associated with a prior diagnosis of ovarian cysts or 
endometriosis, and with ovarian surgery, with a focus on characterizing risk among tumor 
subgroups jointly classified according to the degree of invasiveness and histology. 
 
Materials and Methods 
The study population and methods have been described [12].  Female residents of a thirteen-
county area of western Washington State, 35-74 years of age, diagnosed with a primary invasive 
or borderline epithelial ovarian tumor from 2002 through 2005 were identified through a 
population-based registry that is part of the Surveillance, Epidemiology, and End Results 
program of the US National Cancer Institute.  Of 1,058 eligible women identified, 812 (76.6%) 
were interviewed; of the interviewed cases, 595 had invasive disease.  Tumors were coded by 
registry staff according to the third edition of the International Classification of Diseases for 
Oncology (ICD-O) [13], and these codes were grouped according to guidelines of the World 
Health Organization [14] into the histologic subgroups of serous (n=452), mucinous (n=112), 
endometrioid (n=104), clear cell (n=35), and other epithelial tumors (n=109). In the latter group, 
the most common histologic types were adenocarcinoma, not otherwise specified (NOS, n=34), 
mixed cell adenocarcinoma (n=33), and carcinoma, NOS (n=16).   
 
Controls were selected by random digit dialing [15] using stratified sampling in five-year age 
categories, one-year calendar intervals and two county strata in a 2:1 ratio to women with 
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invasive epithelial ovarian cancer.  For 14,561 (82.0%) of the 17,768 telephone numbers 
belonging to a residence, we determined whether an eligible (i.e., age- and county-eligible and, if 
so, with at least one ovary and no prior history of ovarian cancer) woman resided there.  Of the 
1,561 eligible women identified, 1,313 were interviewed (84.1%).   
 
The study was approved by the Institutional Review Board of the Fred Hutchinson Cancer 
Research Center, and all women provided signed informed consent before participating.   
Information was obtained during an in-person interview, pertained to the period of time before 
diagnosis (for cases) or before an assigned, comparable reference date (for controls), and 
included demographic and lifestyle characteristics, family history of cancer, and menstrual, 
reproductive, and contraceptive history.  Women were asked whether they had ever been 
diagnosed with an ovarian cyst or endometriosis, and, if so, the age at which the condition was 
first diagnosed.  In a separate section of the interview, women were asked to report all ovarian 
surgeries prior to diagnosis or reference date, and the month and year in which these surgeries 
occurred.  Women who reported a prior ovarian surgery were asked to report the amount of 
tissue removed as: part of one or both ovaries; cyst resection; or unilateral oophorectomy. 
 
To reduce the possibility that any increase in risk associated with the diagnosis of a benign 
gynecologic condition might reflect the identification of such a condition consequent to the 
presence or symptoms of a borderline or invasive ovarian tumor that had not yet been identified, 
we excluded from our analyses of the respective variables women whose ovarian cysts (10 
controls and 19 cases) or endometriosis (3 controls and 4 cases) were diagnosed during the year 
before the diagnosis/reference date. Also, we excluded (from the respective analyses) women 
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who reported ovarian surgery for a benign condition during this time frame (1 control and 3 
cases).  (One case reported all three of these exposures within the last year, and so was excluded 
from all analyses.)  Lastly, we excluded five case women who were classified by the tumor 
registry as having primary ovarian cancer, but who reported having had a bilateral oophorectomy 
prior to cancer diagnosis; for most of these women, pathology reports noted the cancer as arising 
in an ovarian remnant.  Because the length of time in which an ovarian tumor may be present, 
but not clinically detectable, is unknown, we also conducted analyses that assessed risk among 
women whose diagnosis of an ovarian cyst or endometriosis and subsequent ovarian surgery was 
at least 5 years before the diagnosis/reference date. 
 
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional 
logistic regression.  Polytomous logistic regression was used for analyses that separated case 
women according to the degree of invasiveness and/or histologic type of the tumor.  For 
borderline tumors, we assessed risks of both mucinous and serous histologic types; other types of 
borderline tumors occurred too infrequently to allow separate analysis.  Histologic types of 
invasive ovarian cancers were grouped as serous, mucinous, endometrioid / clear cell, and 
“other” for analysis; however, because only a small number of mucinous invasive tumors 
occurred (n=23), we present only selected results for this subtype. 
 
Data analyses were conducted using STATA statistical software (version 10.0; STATA 
Corporation, College Station, TX). The analyses were adjusted for the frequency matching 
variables of age, year of diagnosis/reference date, and county of residence as well as duration of 
hormonal contraception and number of full-term births.  Other characteristics examined as 
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potentially confounding the associations of interest included: race/ethnicity; cigarette smoking; 
education; age at menarche; body weight and body mass index (BMI), assessed both at age 30 
years and five years before the reference date; tubal ligation; hysterectomy; use of hormone 
replacement therapy; family history of breast and/or ovarian cancer; personal history of breast 
cancer; and history of infertility. Additional adjustment for these characteristics did not result in 
a meaningful change in odds ratios.   
 
Results 
Characteristics of cases and controls have previously been described [12, 16]. Approximately 
90% of cases and controls were non-Hispanic white women.  Consistent with most prior 
epidemiologic studies of ovarian cancer, cases were less likely than controls to have given birth, 
and reported a lesser extent of exposure to hormonal forms of contraception.  Both a family 
history of ovarian cancer and a personal history of breast cancer were more commonly reported 
by cases than controls. 
 
Unilateral oophorectomy was the most common type of ovarian surgery reported among both 
cases and controls (Table 1).  The remaining ovarian surgeries were reported as excision of a 
cyst or of a partial ovary, and were grouped for analysis.  When the diagnosis of a prior ovarian 
cyst and/or endometriosis was not considered in the analysis, the overall risk of developing a 
borderline tumor was slightly increased among women who had had prior ovarian surgery 
(OR=1.4; 95% CI 0.9-2.2).  The strength of this association did not differ by the extent of 
surgery (i.e., unilateral oophorectomy versus other ovarian surgery; Table 1), and reflected a 
doubling in risk of borderline mucinous tumors, with no alteration in risk noted for borderline 
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serous tumors (Table 2).  In contrast, prior ovarian surgery was associated with a 30% reduction 
in risk (95% CI 0.5-1.1) of invasive ovarian cancer (all types combined; Table 1) in analyses that 
did not incorporate diagnosis of cysts or endometriosis.  A reduction in risk associated with prior 
ovarian surgery was noted for each histologic grouping of invasive ovarian cancers, although 
these results were imprecise (Table 3; only two women who developed an invasive mucinous 
ovarian cancer had undergone ovarian surgery (OR=0.9; data not shown)).   
 
A self-reported history of having had an ovarian cyst (diagnosed by a physician) was associated 
with a small increase in risk of developing a borderline ovarian tumor (OR=1.3, 95% CI 0.9-1.8)   
and did not vary notably according to whether a woman reported ovarian surgery after her cyst 
diagnosis (Table 1).  In analyses that separated tumors by both histology and invasiveness, the 
risk of borderline mucinous tumors was elevated among women with a prior ovarian cyst 
(OR=1.7, 95% CI 1.0-2.8), while risk of borderline serous tumors was not.  The risk of a 
mucinous borderline tumor was, if anything, slightly higher in women who underwent ovarian 
surgery (Table 2).   
 
A history of a prior ovarian cyst (in analyses that did not account for subsequent ovarian surgery) 
was not associated with risk of invasive epithelial ovarian cancer (OR for all histologic types 
combined =1.0, 95% CI 0.7-1.3; Table 1).  However, this association appeared to differ 
according to the receipt of ovarian surgery.  While the risk of invasive disease was marginally 
increased among women who had been diagnosed with a cyst and had no subsequent ovarian 
surgery, it was reduced when a cyst diagnosis was followed by surgery (OR= 0.6, 95% CI 0.4-
0.9, relative to women with no history of a cyst). The reduction in risk associated with surgery 
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following cyst diagnosis was most evident for serous invasive tumors (Table 3) and remained 
present in analyses that considered only surgeries that occurred at least five years before the 
reference date, as well as when women with low-grade serous tumors were excluded (data not 
shown).  Results for “other” histologic types of invasive disease (i.e., those that were not serous, 
mucinous, endometrioid, or clear cell) resembled those for serous tumors (Table 3).  Only four 
invasive mucinous tumors occurred among women with a prior history of ovarian cysts 
(OR=0.9; data not shown).  The types of ovarian surgery reported by women with ovarian cysts 
were fairly similar among cases and controls. 
 
Among women who reported having been diagnosed with endometriosis, we observed no 
association with risk of developing a borderline tumor (Table 1).  There was a suggestion that 
risk of invasive epithelial ovarian cancer associated with a prior diagnosis of endometriosis 
varied according to subsequent ovarian surgery; relative to women with no history of 
endometriosis, the OR was 1.6 (95% CI 1.1-2.3) among women with endometriosis and no 
surgery, while it was 1.2 (95% CI 0.5-2.5) among women with surgery (Table 1).  Also, among 
women with endometriosis who underwent subsequent ovarian surgery, a larger proportion of 
controls (85%) than cases (60%) reported a unilateral oophorectomy.  Among women with 
endometriosis who had undergone a unilateral oophorectomy, the OR was 0.8 (95% CI 0.3-2.1), 
whereas it was 3.3 (95% CI 0.7-15.3) among women with this condition who reported a lesser 
extent of ovarian surgery (i.e., cystectomy or partial oophorectomy; data not shown).   
 
A history of endometriosis was most clearly associated with risk of endometrioid and clear cell 
types of invasive disease; the risk in the combined group of women with either of these tumor 
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types was nearly tripled (Table 3).  Also, in this group, the increased risk associated with not 
having had ovarian surgery was somewhat more pronounced.  The ORs were 3.2 (95% CI 1.9-
5.6) and 1.6 (95% CI 0.4-5.7) among such women who did not or did undergo ovarian surgery, 
respectively, relative to women with no history of endometriosis (Table 3).  However, the small 
number of cases in this tumor subgroup who had had ovarian surgery limited the precision of 
these results.   
 
Discussion 
Strengths of the current study include its population-based design and relatively large size; 
nevertheless, some subgroup analyses were limited by sample size.  Also, similar to most other 
studies that have assessed the relation of ovarian cysts with risk of ovarian cancer, the 
interpretation of our results is limited by the absence of information on the types of ovarian 
abnormalities that occurred, as well as the specific reason that ovarian surgery was performed.  It 
is likely that a range of conditions (e.g., physiologic follicular and corpus luteum cysts; 
endometrioid and dermoid cysts; and benign serous and mucinous tumors) may have been 
reported as ovarian cysts.  The majority of functional ovarian cysts are thought to resolve within 
60-90 days; functional cysts that do not resolve within this time frame, as well as other types of 
ovarian cysts, are more likely to be treated surgically.  The size of a cyst and the age and 
menopausal status of an affected woman may also influence the likelihood of surgical treatment. 
 
We cannot discount the possibility of incomplete or differential recall by cases and controls, nor 
can we exclude the possibility that characteristics associated with willingness to participate in the 
study could have resulted in a non-representative sample of cases or controls.  However, recall 
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bias is unlikely to account for differences in risk across tumor subgroups.  While differing 
response proportions across histologic types could influence our results if the exposures 
examined were linked to our ability to interview cases [16], our response proportions were 
broadly similar and relatively high for women with borderline (80.6%) and invasive (75.4%) 
tumors.  Also, response proportions were similar (ranging from 77% for mucinous invasive to 
88% for endometrioid invasive disease) for all disease subtypes except those grouped as “other 
invasive” (largely undifferentiated) tumors, among whom we interviewed only 53% of eligible 
women. Thus, any bias relating to differential participation according to tumor type, if present, 
might be expected to most strongly influence findings in this latter subgroup.  
 
The exclusion of women whose diagnosis of a benign gynecologic condition or ovarian surgery 
occurred within the year before the diagnosis/reference date was done to reduce possible bias 
resulting from 1) symptoms of an existing, as-yet undiagnosed, cancer leading to these diagnoses 
or surgery or 2) increased or early detection of an asymptomatic tumor during evaluation or 
treatment for a benign condition.  The potential for such a bias to have otherwise influenced our 
findings is suggested by the larger proportion of cases than controls who reported a cyst 
diagnosis in that interval.  However, an additional potential bias must also be considered: relative 
to women without a history of a pelvic condition and/ or surgery (in whom no ovarian evaluation 
is performed), women who undergo ovarian evaluation with no cancer identified will be less 
likely to be diagnosed with ovarian cancer for some time period. This sort of “healthy screenee” 
bias [17] would be expected to lead to spuriously low estimates of ovarian cancer risk associated 
with the diagnosis and/or treatment of some pelvic conditions, at least temporarily. Cognizant of 
this, we performed analyses focusing on cancer risk associated with ovarian surgeries performed 
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at least five years earlier, for by five years it is anticipated that little or no such bias should 
remain.  
 
Only a few studies have assessed ovarian cancer risk in relation to prior ovarian surgery [18-20], 
and none of these provide data regarding risk of disease subtypes or the possible indication for 
surgery.  In a record linkage study in Canada, the risk of invasive or borderline ovarian cancer 
among 18,375 women who had undergone unilateral oophorectomy was substantially increased 
early in the follow-up period (6 months to <2 years after surgery; observed/expected cancers = 
3.8, p<0.001), with no association observed from 2 to more than 10 years after surgery. In two 
other reports, however, unilateral oophorectomy was associated with 40% and 80% reductions in 
risk of ovarian cancer [19, 20].  These disparate results, together with the results of the current 
study, suggest that the indication for surgery-- as well as differences in risk according to tumor 
subtype-- should be considered in studies that examine the influence of ovarian surgery on 
cancer risk. 
 
Prior studies that have assessed whether women with a history of benign ovarian cysts might be 
at altered risk of ovarian cancer provide inconsistent results and, for the most part, do not provide 
data for histology-specific risks and/or risks among women with and without subsequent ovarian 
surgery.  Thus, direct comparisons to the current study are limited.  A large, pooled analysis of 
case-control studies [21] included only those cysts identified as a cause of infertility, and 
reported an overall increased risk of ovarian cancer (OR=1.9, 95% CI 0.8-4.5), with a nearly 4-
fold elevation in risk of serous borderline tumors.  In contrast, ORs of 0.7 and 1.3, both with 
wide confidence bounds, were reported for the association of ovarian cysts and invasive 
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epithelial ovarian cancer in other case-control studies [22, 23].  In one of these [23], subanalyses 
examined the relative frequency of a benign ovarian cyst identified during a histopathologic 
review of the malignant lesion.  Mucinous [relative risk (RR) =12.9, 95% CI 4.2-39.7] and, to a 
lesser extent, endometrioid tumors were categorized as more often arising from a benign cyst 
than were serous tumors.  In a Swedish record linkage study, Borgfeldt [24] reported ORs for 
ovarian cancer of 0.9 (95% CI 0.7-1.1) and 1.2 (95% CI 0.8-1.9) among women with a hospital 
discharge diagnosis of a benign ovarian cyst/tumor and functional cysts, respectively, with no 
information on histology of the ovarian cancer; in contrast to the current study, women who 
underwent ovarian surgery were at a substantially increased risk (OR=8.8, 95% CI 5.2-14.8), 
again with no information on the histology of the malignant tumor.  Crayford et al [25] assessed 
the impact of removal of persistent benign cysts in a cohort of asymptomatic volunteers whose 
cysts were identified via ultrasonography, and reported no decrease in the proportion of expected 
deaths from ovarian cancer relative to other cancers during follow-up.  However, this 
comparison did not allow examination of risk of ovarian cancer (overall or by histologic type) 
independently associated with such asymptomatic cysts and/or their removal; also, a large 
proportion of women who underwent surgical investigation for a cyst had both ovaries removed.   
 
Prior studies assessing the impact of endometriosis are rather consistent in their finding of a 
moderately increased risk of invasive epithelial ovarian cancer, with no increase in risk of 
borderline tumors [4, 24, 26]; however, the influence of ovarian surgery on cancer risk among 
women with endometriosis has not been assessed.  Studies addressing risk in histologic 
subgroups also have observed consistently that the association is attributable to an increased risk 
of endometrioid and clear cell tumors [26, 27], and histopathologic examinations of ovarian 
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tumors provide evidence of a tendency for endometriosis to be present at a higher frequency 
among women with endometrioid and clear cell ovarian tumors than among women with other 
ovarian tumor subtypes [28].   Results of both Swedish [29] and Japanese [27] cohort studies 
suggest that the association of ovarian cancer risk and endometriosis may be greatest among 
women whose endometriosis is present on the ovaries.  The results of the current study are thus 
consistent with prior studies and further raise the possibility (albeit with limited precision) that 
ovarian surgery in women with a diagnosis of endometriosis may lower subsequent cancer risk, 
relative to women with endometriosis who do not undergo ovarian surgery. Because, in the 
current study, we have no data regarding the location (i.e., ovarian or other) of endometriosis 
among women with this diagnosis, our results may 1) underestimate the association of ovarian 
cancer risk associated with the occurrence of ovarian endometriosis and 2) underestimate the 
extent to which ovarian surgery may lower risk among women with ovarian endometriosis. 
 
We observed a moderate increase in risk of developing a borderline mucinous tumor among 
women with a prior ovarian cyst, consistent with the possibility that some benign ovarian 
abnormalities may serve as precursors of this tumor type.  However, risk of this subtype was, if 
anything, further increased among women who reported ovarian surgery after their cyst 
diagnosis.  These results contrast with a recent hypothesis that removal of benign precursor 
lesions may preferentially reduce risk of mucinous tumors [1].  It is possible that benign ovarian 
abnormalities may serve as risk markers, rather than precursors, of subsequent borderline 
mucinous tumors; or that benign precursors of borderline mucinous tumors, if they exist, may 
tend to occur in multiple locations or to reoccur.   
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In contrast, history of a prior ovarian cyst was associated with only a modestly increased risk of 
invasive ovarian cancer, and among women with cysts and subsequent surgery, risk was reduced; 
this pattern was most evident for serous invasive tumors.  While this common subtype of ovarian 
cancer has often been stated to arise “de novo”, indicating a rapid progression in the absence of 
an identifiable precursor, evidence is accumulating to support the existence of a precursor 
(possibly only detectable at the molecular level), either in the ovarian [8] or distal tubal [9] 
epithelium.  Conceivably, such precursors may occur more commonly among women with some 
types of benign ovarian abnormalities, and may further be removed during the course of 
subsequent ovarian surgery.  While our results require replication, they suggest differences in the 
relation of ovarian cysts and endometriosis with risk of specific subtypes of epithelial ovarian 
cancer, as well as the possibility that ovarian surgery after diagnosis of these conditions may 
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Table 1.   Risk of epithelial ovarian cancer in relation to gynecologic diagnoses and ovarian surgery overall and among women 





































OR b (95% CI) 
Ever had ovarian surgeryc     
     No 1182 189 1.0 (ref) 544 1.0 (ref) 733 1.0 (ref) 
     Yes 125 25 1.4 (0.9-2.2) 43 0.7 (0.5-1.1) 68 0.9 (0.6-1.2) 
       Unilateral oophorectomy 75 14 1.4 (0.8-2.6) 28 0.8 (0.5-1.2) 42 0.9 (0.6-1.4) 
       Other type of ovarian surgery 50 11 1.4 (0.7-2.7) 15 0.6 ((0.4-1.2) 26 0.8 (0.5-1.4) 
          Had ovarian surgery at least 5 years before diagnosis/reference date:     
 114 24 1.5 (0.9-2.5) 41 0.8 (0.5-1.1) 65 0.9 (0.7-1.3) 
        
Ever diagnosed with ovarian cystc   
     No 1071 160 1.0 (ref) 481 1.0 (ref) 641 1.0 (ref) 
     Yes 219 47 1.3 (0.9-1.8) 94 1.0 (0.7-1.3) 141 1.1 (0.8-1.3) 
     Ovarian surgery after cystc     
        No 121 29 1.3 (0.8-2.1) 67 1.3 (0.9-1.8) 96 1.3 (1.0-1.8) 
        Yes 95 18 1.2 (0.7-2.1) 25 0.6 (0.4-0.9) 43 0.7 (0.5-1.1) 
            Had ovarian surgery at least 5 years before diagnosis/reference date:     
    86 17 1.3 (0.8-2.3) 23 0.6 (0.4-0.9) 40 0.8 (0.5-1.1) 
        
Ever diagnosed with endometriosisc  
     No 1199 195 1.0 (ref) 521 1.0 (ref) 716 1.0 (ref) 
     Yes 94 17 0.9 (0.5-1.6) 64 1.5 (1.1-2.1) 81 1.3 (1.0-1.8) 
     Ovarian surgery after endometriosisc  
        No 73 12 0.8 (0.4-1.6) 53 1.6 (1.1-2.3) 65 1.4 (1.0-2.0) 
        Yes 20 4 0.9 (0.3-2.8) 10 1.2 (0.5-2.5) 14 1.1 (0.5-2.2) 
            Had ovarian surgery at least 5 years before diagnosis/reference date:
 16 4 1.2 (0.4-3.8) 9 1.3 (0.6-3.0) 13 1.3 (0.6-2.7) 
           
a Numbers in column may not sum to total due to missing values. 
bAdjusted for age, calendar year of diagnosis/reference date, county of residence, number of full term births, and duration of hormonal contraception. 
cFor relevant analyses, excludes women with cysts or endometriosis diagnosed within the year before reference, as well as those whose ovarian surgery occurred 
within the year before the reference date. 
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OR b (95% CI) 
  
Ever had ovarian surgery c    
     No 1182 74 1.0 (ref) 106 1.0 (ref)   
     Yes 125 15 2.0 (1.1-3.7) 9 0.9 (0.4-1.8)   
       Unilateral oophorectomy 75 8 1.9 (0.9-4.2) 6 1.0 (0.4-2.4)   
       Other type of ovarian surgery 50 7 2.2 (0.9-5.3) 3 0.7 (0.2-2.3)   
          Had ovarian surgery at least 5 years before diagnosis/reference date:    
 114 15 2.3 (1.2-4.3) 8 0.9 (0.4-1.9)   
        
Ever  diagnosed with ovarian cystc    
     No 1071 62 1.0 (ref) 90 1.0 (ref)   
     Yes 219 24 1.7 (1.0-2.8) 21 1.0 (0.6-1.6)   
     Ovarian surgery after cyst c     
        No 121 13 1.7 (0.9-3.2) 15 1.2 (0.7-2.2)   
        Yes 95 11 1.8 (0.9-3.6) 6 0.7 (0.3-1.7)   
            Had ovarian surgery at least 5 years before diagnosis/reference date: 
    86 11 2.1 (1.0-4.2) 5 0.7 (0.3-1.8)   
        
Ever diagnosed with endometriosis c 
     No 1199 80 1.0 (ref) 106 1.0 (ref)   
     Yes 94 6 0.9 (0.4-2.2) 10 0.9 (0.5-2.0)   
     Ovarian surgery after endometriosis c 
        No 73 3 0.7 (0.2-2.2) 8 1.0 (0.4-2.3)   
        Yes 20 3 1.6 (0.4-5.8) 1 0.4 (0.1-3.3)   
            Had ovarian surgery at least 5 years before diagnosis/reference date:
 16 3 2.2 (0.6-8.1) 1 0.6 (0.1-4.5)   
        
        
           
a Numbers in column may not sum to total due to missing values. 
bAdjusted for age, calendar year of diagnosis/reference date, county of residence, number of full term births, and duration of hormonal contraception. 
cFor relevant analyses, excludes women with cysts or endometriosis diagnosed within the year before reference, as well as those whose ovarian surgery occurred 
within the year before the reference date. 
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OR b (95% CI) 
Ever had ovarian surgery c    
     No 1182 304 1.0 (ref) 121 1.0 (ref) 98 1.0 (ref) 
     Yes 125 26 0.8 (0.5-1.2) 10 0.8 (0.4-1.6) 5 0.5 (0.2-1.3) 
       Unilateral oophorectomy 75 17 0.8 (0.5-1.4) 6 0.8 (0.3-2.0) 3 0.5 (0.2-1.6) 
       Other type of ovarian surgery 50 9 0.7 (0.3-1.4) 4 0.7 (0.3-2.2) 2 0.5 (0.1-2.1) 
          Had ovarian surgery at least 5 years before diagnosis/reference date:    
 114 26 0.8 (0.5-1.3) 9 0.8 (0.4-1.6) 4 0.4 (0.2-1.2) 
        
Ever  diagnosed with ovarian cyst c   
     No 1071 284 1.0 (ref) 94 1.0 (ref) 84 1.0 (ref) 
     Yes 219 45 0.8 (0.6-1.1) 30 1.5 (0.9-2.4) 15 0.9 (0.5-1.6) 
     Ovarian surgery after cyst c     
        No 121 33 1.1 (0.7-1.7) 20 1.9 (1.1-3.2) 11 1.2 (0.6-2.3) 
        Yes 95 11 0.4 (0.2-0.8) 9 1.0 (0.5-2.1) 4 0.5 (0.2-1.5) 
            Had ovarian surgery at least 5 years before diagnosis/reference date: 
    86 11 0.5 (0.2-0.9) 8  1.0 (0.4-2.1) 3 0.5 (0.1-1.5) 
        
Ever diagnosed with endometriosis c 
     No 1199 298 1.0 (ref) 105 1.0 (ref) 96 1.0 (ref) 
     Yes 94 31 1.3 (0.9-2.1) 26 2.8 (1.7-4.7) 7 0.9 (0.4-2.0) 
     Ovarian surgery after endometriosis c 
        No 73 24 1.3 (0.8-2.2) 23 3.2 (1.9-5.6) 6 0.9 (0.4-2.3) 
        Yes 20 6 1.3 (0.5-3.2) 3 1.6 (0.4-5.7) 1 0.7 (0.1-5.1) 
            Had ovarian surgery at least 5 years before diagnosis/reference date:
 16 6 1.5 (0.6-3.9) 2 1.5 (0.3-6.7) 1 0.8 (0.1-6.5) 
        
        
           
a Numbers in column may not sum to total due to missing values. 
bAdjusted for age, calendar year of diagnosis/reference date, county of residence, number of full term births, and duration of hormonal contraception. 
cFor relevant analyses, excludes women with cysts or endometriosis diagnosed within the year before reference, as well as those whose ovarian surgery occurred 
within the year before the reference date. 
 
